



SAFETY OF PEMBROLIZUMAB +/- CHEMOTHERAPY IN FIRST-LINE METASTATIC NON-SMALL CELL LUNG CARCINOMA IN REAL-WORLD PRACTICE

Cárdenas Sierra M., Goikolea Ugarte FJ., Gómez de Segura Sarobe A., Núñez Ceruelo I., Palacios Filardo M., Miron Elorriaga G., Martín Torrente A., Viseda Torrellas Y., Torio Álvarez L., Ibarra Barrueta O. Pharmacy Service, Hospital Galdakao-Usansolo

BACKGROUND

- ✓ Cancer patients with comorbidities are usually excluded from clinical trials.
- ✓ Real-life observational studies are of particular interest to elucidate the safety of these new therapies.
- ✓ Safety of pembrolizumab +/- chemotherapy (QT) in metastatic non-small cell lung carcinoma (mNSCLC)
 - ➔ Assessed in KEYNOTE-024, 189 and 407 pivotal trials

OBJETIVE

To assess the safety of pembrolizumab +/- platinum-based QT in first-line treatment of mNSCLC in real life.

MATERIALS AND METHODS

Observational, retrospective, single-center study
130 adult patients.
From December 1, 2017 to December 31, 2022

INCLUSION CRITERIA

- Stage IV NSCLC treated in first-line
- Performance status 0-1
- Without EGFR or ALK mutations
- Without autoimmune diseases
- Without brain metastases

DATABASE

Adverse events (AEs) from electronic medical records. CTCAE Version 5.0.

TREATMENTS

Until progression or toxicity for a max. of 2 years

PD-L1 ≥ 50% ANY HISTOLOGY

Pembrolizumab 200 mg or 2 mg/kg IV every 3 w

PD-L1 < 50% NON-SQUAMOUS HISTOLOGY

Pembrolizumab every 3 w 4 cycles
+ cisplatin IV 75 mg/m² or carboplatin IV 6 AUC
+ pemetrexed IV 500 mg/m²
plus maintenance pembrolizumab + pemetrexed

PD-L1 < 50% SQUAMOUS HISTOLOGY

Pembrolizumab every 3 w 4 cycles
+ carboplatin IV 6 AUC
+ paclitaxel IV 200mg/m²
plus maintenance pembrolizumab

RESULTS

	Any grade	Grade 3-4
Total AEs	491	78
AEs INCIDENCE >15%		
Anemia	36	11
Anorexia	51	2
Asthenia	96	10
Nausea	43	3
Diarrhea	25	2
Constipation	20	0
Mucositis	21	2
Neurotoxicity	21	1
INMUNOMEDIATED Aes		
Hepatotoxicity	7	3
Nephritis	3	1
Myocarditis	1	1
Duodenojejunitis	1	1
Pneumonitis	1	0

10 patients discontinued treatment due to toxicity

CONCLUSION

Most patients suffered more than one AE. Even so, no deaths have been related to toxicity (there were no grade 5 AE). The 6 grade 3-4 immune-mediated AEs should be highlighted.

5PSQ-044

